Get the Stockscreener App
5.82
0.17%
0.01
Champions Oncology Inc stock is traded at $5.82, with a volume of 2,483.
It is up +0.17% in the last 24 hours and up +1.75% over the past month.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
See More
Previous Close:
$5.81
Open:
$6.16
24h Volume:
2,483
Relative Volume:
0.29
Market Cap:
$80.82M
Revenue:
$57.94M
Net Income/Loss:
$-2.34M
P/E Ratio:
-34.93
EPS:
-0.1666
Net Cash Flow:
$3.82M
1W Performance:
+1.04%
1M Performance:
+1.75%
6M Performance:
-14.16%
1Y Performance:
-33.94%
1-Day Range:
$5.82
$6.16
1-Week Range:
$5.55
$6.16
52-Week Range:
$5.50
$8.98
Champions Oncology Inc Stock (CSBR) Company Profile
Name
Champions Oncology Inc
Sector
Industry
Phone
410-369-0365
Address
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.82 | 80.82M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-12-24 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-18-19 | Initiated | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Stock (CSBR) Latest News
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
CSBR Q4'25 Earnings: revenue estimate is 12.89M USD - TradingView
Champions Oncology (CSBR) Holds Steady Near Support as Traders Await DirectionIchimoku TK Cross - dars.gov.et
IMMP Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
(CSBR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Enterprise value to revenue forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Global Oncology-Based In-Vivo CRO Market to Accelerate Substantially at a CAGR of ~8% by 2034 | DelveInsight - The AI Journal
ENGN Q1 2026 Earnings: Loss Narrows as EPS Beats ExpectationsFree Cash Flow Trends - dars.gov.et
Price to sales forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Price to sales forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
“Publish or Perish”: Should Science Rethink Success Metrics? - Technology Networks
Price to earnings forward of Champions Oncology, Inc. – NASDAQ:CSBR - TradingView
Enterprise value to EBITDA forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
Price to book forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
Price to earnings forward of Champions Oncology, Inc. – FWB:2I3 - TradingView
Champions Oncology, Inc. Actuals & Estimates (NASDAQ:CSBR) - TradingView
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology to Announce First Quarter Financial Results on Monday, September 16, 2019 - ACCESS Newswire
Registration Opens for JADPRO Live 2026: Advanced Practitioners Gather in the Heartland to Champion High-Quality Cancer Care - Yahoo! Finance Canada
Champions Oncology Inc (CSBR) Valuation: PE, PB & Fair Value Analysis - TradingKey
LAR Q1 2026 Earnings: EPS Misses Estimates, Revenue Not Reported, Stock DeclinesEBITDA Estimate Trend - dars.gov.et
Price-Driven Insight from (CSBR) for Rule-Based Strategy - Stock Traders Daily
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Champions Oncology Inc (CSBR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology Inc (CSBR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Champions Oncology Inc (CSBR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Champions Oncology Inc (CSBR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
12 Health Care Stocks Moving In Tuesday's After-Market Session - Sahm
TXNM Energy, Inc. Files Form 8-K With SEC: Company Information, Stock, and Contact Details - Minichart
Hong Kong IPO Boom Faces Performance Challenges as Post-Listing Returns FadeEarnings Weakness Phase - newsline.com
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
As the GLP-1 race heats up, how can investors position themselves for the next wave of innovation? (LLY:NYSE) - Seeking Alpha
(CSBR) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
LCTX Q1 2026 Earnings: EPS Misses Estimates as Cell Therapy Pipeline AdvancesEarnings Weakness Phase - dars.gov.et
Check For Cancer Champion Dr. Ryan Schoenfeld Has a Vision For Earlier Detection - ACCESS Newswire
Check for Cancer Champion Dr. Ryan Schoenfeld has a vision for earlier detection - Aflac Newsroom
Vail Resorts (MTN) Edges Higher as Ski Season Momentum BuildsModified Schiff - newsline.com
AQU PE Ratio & Valuation, Is AQU Overvalued - Intellectia AI
CSBR Q1 2026 Earnings: EPS Misses Estimates by Wide Margin, Stock Edges HigherBook Value Growth - newsline.com
CSBR Q1 2026 Earnings: Earnings Miss Hides Underlying Progress in Oncology PlatformCFO Commentary Report - newsline.com
Champions Oncology Q1 2026 Earnings: EPS Miss of 121.79% Weighs on Results Despite Modest Stock Gain - newsline.com
CGI Inc. (GIB) Faces Pressure: Stock Drops Nearly 4% as Support Levels ApproachPre-Earnings Momentum - newsline.com
CSBR Technical Analysis & Stock Price Forecast - Intellectia AI
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer - Yahoo Finance UK
CSBR Q1 2026 Earnings: EPS Misses Estimates, Stock Gains SlightlyConsensus Beat Rate - dars.gov.et
(CSBR) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Medidata Champions Collaborative Scientific Advancement at ASCO with New Research on Oncology Protocol Optimization and CAR T Efficacy - marketscreener.com
Champions Oncology Inc. (CSBR) Q1 2026 Earnings: Earnings Miss Estimates as EPS Falls to -$0.02Special Dividend Alert - The Legal Advocate
Champions Oncology Inc Stock (CSBR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):